News & Insights

A new bipartisan Senate proposal could reshape access to one of the most effective medications for opioid use disorder by allowing certain

A new class of synthetic opioids known as nitazenes is drawing urgent attention from public health and addiction experts as the U.S. drug

The U.S. Food and Drug Administration has approved Rextovy, a 4 mg naloxone hydrochloride nasal spray, for over-the-counter use, expanding

The Cherokee Nation is using opioid settlement funds to build a new treatment center in Tahlequah, Oklahoma, offering a powerful example of

A growing shift in the treatment of alcohol use disorder (AUD) is reshaping how clinicians, health systems, and recovery communities think

A New York Times report is drawing new attention to the intersection of vaping regulation, FDA oversight, and political influence in public

New federal data show that U.S. drug overdose deaths declined for the third straight year in 2025, a notable milestone in the nation’s

New research in the Journal of Substance Use & Addiction Treatment highlights the growing potential of smart harm reduction vending machines

A new federal policy shift is intensifying debate around harm reduction, overdose prevention, and the nation’s response to the fentanyl

Purdue Pharma, the maker of OxyContin, has officially ceased operations as part of its long-running bankruptcy resolution, marking a major

President Donald Trump’s recent executive order easing some federal restrictions on psychedelic substances is drawing national attention to

A major change in federal cannabis policy could reshape conversations across healthcare, pharmacy, addiction medicine, and public policy